Principal Investigator
Peter Hosein
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231138
Clinical Trial Summary
A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Pancreatic, Liver, and Related Cancers
Contact Information
Phone Number
305-243-2647